SpringWorks Therapeutics (SWTX)
(Delayed Data from NSDQ)
$38.91 USD
-0.36 (-0.92%)
Updated Jun 4, 2024 04:00 PM ET
After-Market: $38.97 +0.06 (0.15%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth A Momentum F VGM
Brokerage Reports
SpringWorks Therapeutics [SWTX]
Reports for Purchase
Showing records 1 - 20 ( 188 total )
Company: SpringWorks Therapeutics
Industry: Medical - Biomedical and Genetics
Company: SpringWorks Therapeutics
Industry: Medical - Biomedical and Genetics
Company: SpringWorks Therapeutics
Industry: Medical - Biomedical and Genetics
Making Mature Progress on Multiple Fronts; Modulating PT to $74
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: SpringWorks Therapeutics
Industry: Medical - Biomedical and Genetics
Mirdametinib Rolling Towards the NF1-PN Market
Provider: Wedbush Securities Inc.
Analyst: NIERENGARTEN D
Company: SpringWorks Therapeutics
Industry: Medical - Biomedical and Genetics
Company: SpringWorks Therapeutics
Industry: Medical - Biomedical and Genetics
Company: SpringWorks Therapeutics
Industry: Medical - Biomedical and Genetics
Company: SpringWorks Therapeutics
Industry: Medical - Biomedical and Genetics
Company: SpringWorks Therapeutics
Industry: Medical - Biomedical and Genetics
Company: SpringWorks Therapeutics
Industry: Medical - Biomedical and Genetics
2024 Top Picks: Seeing Important Turnaround Year While Watching the Macro
Provider: H.C. Wainwright & Co., Inc.
Analyst: Research Department
Company: SpringWorks Therapeutics
Industry: Medical - Biomedical and Genetics
2024 Top Picks: Seeing Important Turnaround Year While Watching the Macro
Provider: H.C. Wainwright & Co., Inc.
Analyst: Research Department
Company: SpringWorks Therapeutics
Industry: Medical - Biomedical and Genetics
Company: SpringWorks Therapeutics
Industry: Medical - Biomedical and Genetics
Company: SpringWorks Therapeutics
Industry: Medical - Biomedical and Genetics
Further Revising OGSIVEO Forecasts Upward; Raising PT to $73
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: SpringWorks Therapeutics
Industry: Medical - Biomedical and Genetics
Company: SpringWorks Therapeutics
Industry: Medical - Biomedical and Genetics
Nirogacestat Receives FDA Approval For Desmoid Tumors; Raising PT to $64
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: SpringWorks Therapeutics
Industry: Medical - Biomedical and Genetics
HEALTHCARE - The Week Ahead in Life Sciences
Provider: Wedbush Securities Inc.
Analyst: NIERENGARTEN D
Company: SpringWorks Therapeutics
Industry: Medical - Biomedical and Genetics
Optimized Entry and Exit Levels for SWTX 112223
Provider: Stock Traders Daily
Analyst: Research Department
Company: SpringWorks Therapeutics
Industry: Medical - Biomedical and Genetics
Mirdametinib Delivers; Nirogacestat FDA Decision Looms; Lowering PT to $52
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R